Market research
TG4.F Oxurion NV
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 267
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.58
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BE0003846632
- Market cap
- 267
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.58
About
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TG4.F discussion.
5 years, 5 months ago
Oxurion NV is currently in a long term downtrend where the price is trading 5.7% below its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.0.
Oxurion NV's total revenue sank by 0.0% to $1M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 8.0% to $-6M since the same quarter in the previous year.
Based on the above factors, Oxurion NV gets an overall score of 2/5.